Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenue	$ 181,157	$ 192,925	$ 153,612
Cost of goods sold	59,828	69,133	51,821
Gross profit	121,329	123,792	101,791
Operating expenses:
Research and development	21,019	32,337	26,421
Clinical and regulatory affairs	12,952	16,215	15,418
Marketing and sales	92,400	107,759	78,213
General and administrative	35,301	41,044	29,581
Restructuring costs	1,477	11,093	0
Settlement costs	0	4,650	0
Contract termination and business acquisition expenses	0	5,768	5,071
Total operating expenses	163,149	218,866	154,704
Loss from operations	(41,820)	(95,074)	(52,913)
Other income (expense):
Interest income	83	228	175
Interest expense	(22,064)	(15,841)	(7,476)
Other income (expense), net	554	(2,161)	553
Change in fair value of contingent consideration related to acquisition	2,900	2,500	(100)
Loss on extinguishment of debt	(6,512)	0
Change in fair value of derivative liabilities	0	(43,831)	0
Total other income (expense)	(25,039)	(59,105)	(6,848)
Net loss before income tax	(66,859)	(154,179)	(59,761)
Income tax benefit (expense)	459	(498)	9,337
Net loss	(66,400)	(154,677)	(50,424)
Other comprehensive income (loss) foreign currency translation	1,847	978	(1,762)
Comprehensive loss	$ (64,553)	$ (153,699)	$ (52,186)
Basic and diluted net loss per share (in USD per share)	$ (0.80)	$ (1.91)	$ (0.75)
Shares used in computing basic and diluted net loss per share (in shares)	83,325	80,976	67,671